ClinicalTrials.Veeva

Menu

Predictive Role of sTREM in Endovascular Thrombectomy Outcomes

X

Xuzhou Medical University

Status

Enrolling

Conditions

Acute Ischemic Stroke

Study type

Observational

Funder types

Other

Identifiers

NCT06545591
XYFY2024-KL335-01

Details and patient eligibility

About

Soluble triggering receptor expressed on myeloid cells (sTREM), which reflects microglia activation, has been reported closely associated with neuronal injury and neuroinflammation. This study is to investigatethe prognostic roles of sTREM (sTREM1 and sTREM2) in patients with ischemic stroke who underwent endovascular thrombectomy (EVT).

Full description

For acute ischemic stroke, the current treatment strategy involves timely recanalization by intravenous thrombolysis and endovascular thrombectomy (EVT). Patients receiving EVT are more likely to achieve successful revascularization and long--term functional independence compared with those receiving standard medical treatment.1 In patients receiving EVT, significant predictors of a favorable functional outcome include minor initial stroke severity, successful recanalization, and shorter onset--to--treatment time. However, unfavorable outcomes can occur even after early successful recanalization in some cases.Triggering receptors expressed on myeloid cells (TREM-1 and TREM-2) are a familyof receptors involved in the immune system expressed on a variety of innate cells of the myeloid lineage, including microglia. sTREM, which reflects microglia activation, has been reported closely associated with neuronal injury and neuroinflammation. We enrolled adult patients with stroke who received EVT, with blood sampling immediately before (T1) and after EVT (T2), and at 24 hours after EVT (T3). Non--stroke controls and patients with non--EVT stroke were also enrolled. The plasma concentration of sTREM1 and sTREM2 were analyzed by ELISA. The medical information, image findings and levels of plasma sTREM1 and sTREM2 were analyzed to clarify the association with poor functional outcome (modified Rankin Scale 4-6) at 3 months after stroke.

Enrollment

300 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients > 18 years old.
  • Patients with acute large vessel occlusion within 24 hours of onset who will receive endovascular treatment.

Exclusion criteria

  • Impossibility of getting a blood sample.
  • Impossibility of performing the test (Invalid results).
  • Refusal to provide the informed consent by the patient/relative.

Trial design

300 participants in 3 patient groups

EVT-stroke group
Description:
Patients with ischemic stroke who received endovascular thrombectomy (EVT) treatment
non--EVT stroke group
Description:
The non--EVT stroke group was composed of patients with ischemic stroke without endovascular thrombectomy (EVT) treatment during the same period
non--stroke control group
Description:
The non--stroke control group was composed of randomly selected stroke--free, age--matched and sex--matched individuals recruited from the health examination center.

Trial contacts and locations

1

Loading...

Central trial contact

Xingzhi Wang, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems